Brief: Dyadic Receives Regulatory Approval To Initiate Phase 1 Clinical Trial

Dyadic International

27/10/2022 17:16

Oct 27 (Reuters) - Dyadic International Inc  DYAI.O :
    * DYADIC RECEIVES REGULATORY APPROVAL TO INITIATE PHASE 1
CLINICAL
TRIAL  TO DEMONSTRATE CLINICAL SAFETY AND EFFICACY IN HUMANS FOR
DYAI-100 COVID-19 RECOMBINANT PROTEIN RBD BOOSTER VACCINE
CANDIDATE
    * DYADIC INTERNATIONAL - PREPARATIONS UNDERWAY TO INITIATE
PHASE 1
CLINICAL TRIAL TO EVALUATE SAFETY OF DYAI-100 COVID-19 RBD
BOOSTER VACCINE
    * DYADIC INTERNATIONAL - PREPARATIONS UNDERWAY TO INITIATE
PHASE 1
CLINICAL TRIAL TO EVALUATE IMMUNOGENICITY OF DYAI-100 COVID-19
RBD BOOSTER VACCINE
    * DYADIC INTERNATIONAL - PREPARATIONS UNDERWAY TO INITIATE
PHASE 1
CLINICAL TRIAL WITH CURRENT PLANS TO BEGIN ENROLLING PATIENTS
LATER THIS YEAR IN SOUTH AFRICA

Source text for Eikon:  ID:nGNX2xMMrB 
Further company coverage:  DYAI.O 
 ((Reuters.Briefs@thomsonreuters.com;))